|By PR Newswire||
|December 25, 2013 08:00 AM EST||
NEW YORK, December 25, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Charles River Laboratories (NYSE: CRL), The Medicines Company (NASDAQ: MDCO), Bio-Reference Laboratories Inc. (NASDAQ: BRLI), HeartWare International Inc. (NASDAQ: HTWR) and Haemonetics Corporation (NYSE: HAE). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Charles River Laboratories Research Report
On December 20, 2013, Charles River Laboratories' (Charles River) stock rose 0.88%, ending the day's session at $52.75. Over the previous three trading sessions, shares of Charles River gained 1.11%, compared to the S&P 500 Index, which gained 2.10% during the same period. The Full Research Report on Charles River Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
The Medicines Company Research Report
On December 20, 2013, The Medicines Company's (The Medicines Company) stock rose 3.02%, ending the day's trading session at $37.92. Over the previous three trading sessions, shares of The Medicines Company gained 3.41%, compared to the Nasdaq Composite Index, which gained 2.01% during the same period. The Full Research Report on The Medicines Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Bio-Reference Laboratories Inc. Research Report
On December 19, 2013, Bio-Reference Laboratories Inc. (Bio-Reference) reported its Q4 FY 2013 and full-year FY 2013 (period ended October 31, 2013) financial results. The Company's net revenues increased 17.6% YoY to $192.2 million during the quarter and the same increased 16.5% YoY to $715.4 million in full-year FY 2013. Net income was $11.1 million or $0.40 per diluted share in Q4 FY 2013, compared to net income of $12.9 million or $0.46 per diluted share in Q4 FY 2012. Net income was $45.8 million or $1.65 per diluted share in full-year FY 2013, compared to net income of $42.2 million or $1.51 per diluted share in full-year FY 2012. Commenting on the results, Marc D. Grodman, M.D., CEO of Bio Reference, said, "Nonetheless, over the past year, specifically during the fourth quarter of FY13, we identified a significant reduction in reimbursement, particularly from commercial payers. We previously disclosed that we had identified a sequential drop in quarterly revenue, excluding our genetic testing revenues, in the aggregate amount of approximately 4% from Q3FY13 to Q4FY13. The reduction in reimbursement from payers is an industry-wide issue that we believe has been observed by many companies in our space. Simultaneously, we experienced significant expenses relating to the integration of our acquisitions in Florida and California as well as the initial rollout of our Inherited Cancers program at GeneDx. While the expenses related to the integration of acquisitions and the Inherited Cancer program adversely affected our Q4FY13 results of operations, we believe they will also be the foundations for our growth in 2014 and beyond." The Full Research Report on Bio-Reference Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
HeartWare International Inc. Research Report
On December 20, 2013, HeartWare International Inc. (HeartWare) announced that the Company's CEO Doug Godshall is scheduled to make a presentation at the 32nd Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PT (4:30 p.m. ET) on Tuesday, January 14, 2014. The Company added that the conference will be held from January 13, 2014 to January 16, 2014 at the Westin St. Francis Hotel in San Francisco. HeartWare informed that interested parties may access a live webcast of the presentation at the conference via a link available at the Company's website. The Full Research Report on HeartWare International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Haemonetics Corporation Research Report
On December 20, 2013, Haemonetics Corporation (Haemonetics) announced that the Company will report its Q3 FY 2014 financial results on January 27, 2014, before the market opens. Haemonetics added that it will host a conference call to discuss and answer questions about the press release at 8:00 a.m. ET on the same day. According to the Company, interested parties can access a live webcast of the conference call via Haemonetics' website. The Full Research Report on Haemonetics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner